Search results for "ACTIVATOR"

showing 10 items of 488 documents

Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated hep…

2003

Item does not contain fulltext OBJECTIVES: The aim of this study was to evaluate percutaneous coronary intervention (PCI) in the Assessment of the Safety and Efficacy of New Thrombolytic Regimens (ASSENT-3) trial. BACKGROUND: In the ASSENT-3 trial, co-therapy with abciximab (ABC) or enoxaparin (ENOX) reduced ischemic complications after ST-elevation acute myocardial infarction treated with tenecteplase when compared with unfractionated heparin (UFH). The effect of these new co-therapies on the results of PCI is unknown. METHODS: Clinical outcomes in patients who received co-therapy with ABC, ENOX, or UFH and subsequently underwent an elective (n = 1,064) or urgent (n = 716) PCI in the ASSEN…

MaleAbciximabmedicine.medical_treatmentMyocardial InfarctionAlbertaBelgiumRecurrenceGermanyAbciximabAngioplasty Balloon CoronaryHeart lung and circulation [UMCN 2.1]Netherlandseducation.field_of_studyAntibodies MonoclonalMiddle AgedTreatment OutcomeItalyElective Surgical ProceduresTissue Plasminogen ActivatorDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicineEnoxaparin sodiummedicine.drugmedicine.medical_specialtymedicine.drug_classPopulationLow molecular weight heparinTenecteplasePlatelet Glycoprotein GPIIb-IIIa ComplexDrug Administration ScheduleImmunoglobulin Fab FragmentsFibrinolytic AgentsInternal medicineNorth CarolinamedicineHumansEnoxaparineducationEmergency TreatmentSwedenHeparinbusiness.industryAnticoagulantsPercutaneous coronary interventionSurvival AnalysisSurgerySpainConventional PCITenecteplasebusinessFibrinolytic agentJournal of the American College of Cardiology
researchProduct

Plaque and blood vulnerability in ST segment elevation myocardial infarction patients: association between lesion morphology using intravascular ultr…

2013

AIM The purpose of the study was to evaluate associations between iMap intravascular ultrasound tissue characterization of culprit and nonculprit lesions in infarct-related artery and plasma biomarkers during ST segment elevation myocardial infarction (STEMI) and at 10-month follow-up. METHODS AND RESULTS Sixty-three STEMI patients at the time of index hospitalization and 10-month follow-up underwent coronary angiography and intravascular ultrasound with iMap tissue characterization of the culprit artery. Proximal and culprit segments were analyzed. A higher percentage of necrotic tissue in the nonculprit segment was found in patients in the top soluble intercellular adhesion molecule 1 (sI…

MaleAcute coronary syndromemedicine.medical_specialtyTime FactorsMyocardial InfarctionCoronary AngiographyCulpritLesionchemistry.chemical_compoundNecrosisPercutaneous Coronary InterventionPredictive Value of TestsInternal medicineIntravascular ultrasoundPlasminogen Activator Inhibitor 1medicineST segmentHumansMyocardial infarctionProspective StudiesUltrasonography InterventionalAgedmedicine.diagnostic_testbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseIntercellular Adhesion Molecule-1Coronary VesselsFibrosisPlaque Atheroscleroticmedicine.anatomical_structureTreatment OutcomechemistryPlasminogen activator inhibitor-1CardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersArteryCoronary artery disease
researchProduct

Therapeutic Application of 20-kHz Transcranial Ultrasound in an Embolic Middle Cerebral Artery Occlusion Model in Rats

2007

Background and Purpose— Therapeutic application of diagnostic ultrasound has been shown to improve recanalization rates in patients with acute cerebral vessel occlusion. There is experimental evidence that low-frequency ultrasound may be superior. This study was designed to evaluate the therapeutic efficacy and safety of low-frequency ultrasound in an embolic middle cerebral artery occlusion model in rats. A parameter setting was used that had not previously shown any side effects and interactions with healthy rat brain tissue. Methods— Male Wistar rats were submitted to middle cerebral artery clot embolism and transcranial treatment with 20-kHz continuous-wave ultrasound (0.2 W/cm 2 ), ei…

MaleAdvanced and Specialized Nursingbusiness.industryUltrasonic Therapymedicine.medical_treatmentUltrasoundInfarction Middle Cerebral ArteryThrombolysismedicine.diseaseRatsTranscranial DopplerDisease Models AnimalEmbolismmedicine.arteryAnesthesiaMiddle cerebral arteryOcclusionmedicineAnimalsNeurology (clinical)Rats WistarCardiology and Cardiovascular MedicinebusinessPlasminogen activatorStrokeStroke
researchProduct

Post-transcriptional analysis of rat mitochondrial D-3-hydroxybutyrate dehydrogenase control through development and physiological stages.

1991

Abstract The nuclear encoded mitochondrial D -3-hydroxybutyrate dehydrogenase (BDH) is synthesized in the cytosal as a larger precursor. This membrane enzyme which requires lecithin for activity plays an essential role in energy metabolism as a ketone bodies-converting enzyme. A cDNA clone of the rat liver enzyme encompassing an antigenic determinant peptide has been isolated after immunoscreening of a λ gt11 expression library. The nucleotide sequence of this 279-base cDNA insert contains a single open reading frame of 93 amino-acids, which represents about a third of the mature enzyme. Amino-acid sequence analysis predicts a hydrophobic stretch of 29 amino-acids long which probably functi…

MaleAgingBlotting WesternMolecular Sequence DataBiologyGene Expression Regulation EnzymologicEnzyme activatorHydroxybutyrate DehydrogenaseComplementary DNAImmunoscreeningGene expressionAnimalsAmino Acid SequenceCloning MolecularRNA Processing Post-TranscriptionalGenechemistry.chemical_classificationMessenger RNASex CharacteristicsBase SequenceEstradiolRats Inbred StrainsCell BiologyGeneral MedicineDNABlotting NorthernEmbryo MammalianMolecular biologyDietary FatsMitochondriaRatsOpen reading frameEnzymeBiochemistrychemistryOrgan SpecificityFemaleCorticosteroneBiology of the cell
researchProduct

Differential expression of PGC-1α and metabolic sensors suggest age-dependent induction of mitochondrial biogenesis in Friedreich ataxia fibroblasts.

2011

11 pages, 6 figures. PMID:21687738[PubMed] PMCID: PMC3110204

MaleAgingMitochondrial DiseasesMitochondrial MyopathyUbiquinoneCardiomyopathylcsh:MedicineMitochondrionAMP-Activated Protein Kinasesp38 Mitogen-Activated Protein KinasesAntioxidantsAdenosine TriphosphateAMP-activated protein kinaseTrinucleotide RepeatsFibrosisMolecular Cell BiologyChildlcsh:ScienceHeat-Shock ProteinsRegulation of gene expressionMultidisciplinaryMovement DisordersbiologyNeuromuscular DiseasesMiddle AgedCatalasePeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaCell biologyMitochondriaDNA-Binding ProteinsNeurologyDisease ProgressionMedicineFemalemedicine.symptomSignal TransductionResearch ArticleAdultcongenital hereditary and neonatal diseases and abnormalitiesAtaxiaAdolescentMitochondrial ProteinsmedicineGeneticsHumansBiologyAllelesGlutathione PeroxidaseSuperoxide Dismutaselcsh:RHuman GeneticsFibroblastsmedicine.diseaseMolecular biologyOxidative StressMitochondrial biogenesisGene Expression RegulationFriedreich Ataxiabiology.proteinFrataxinlcsh:QEnergy MetabolismReactive Oxygen SpeciesTranscription FactorsPLoS ONE
researchProduct

SARS CoV2 infection _The longevity study perspectives

2021

Graphical abstract

MaleAgingssRNA single-stranded RNARFLP restriction fragment length polymorphismHSPs heat shock proteinsReviewPTMs post-translational modificationsSevere Acute Respiratory SyndromeBiochemistryHIV-1 human immunodeficiency virus-1TNF-α tumor necrosis factor-αEC endothelial cells0302 clinical medicineFluAV influenza A virusI insertionMedicineIFN-γ interferon-γDIC disseminated intravascular coagulationPCR Polymerase Chain Reactionmedia_commonAged 80 and overLongevityRBD receptor-binding domainNeurologyLongevity modelMI myocardial infarctionNK natural killerhPIV2 human parainfluenza virus type 2media_common.quotation_subjectResearching genetic basis of resistance and potential pharmacological targetsLongevityDBP diastolic blood pressureNF-Kb nuclear transcription factor kBRANTES regulated upon activation normal T cell expressed and secretedMphi human macrophages03 medical and health sciencesCox 2 cyclooxygenase 2ORF open reading framePT prothrombin timeSettore MED/05 - Patologia ClinicaHumansMolecular BiologyInflammatory genesARDS acute respiratory distress syndromeNO nitric oxideD deletionCpGIs CpG islandsT2DM type 2 diabetes mellitusmedicine.diseaseFDP fibrin degradation products030104 developmental biologySARS CoV2 severe acute respiratory syndrome Coronavirus 2 virusImmunologyBMI body max indexItalian nonagenarians/centenariansRSV respiratory syncytial virusComplication030217 neurology & neurosurgeryMAPK mitogen-activated protein kinaseIP-10 IFN-γ -Inducible Protein 1040301 basic medicineAT1R activity of angiotensin 1 receptorsDCs dentritic cellsSSCP single strand conformation polymorphismACE/DD polymorphism of the angiotensin converting enzymeFGF21 fibroblast growth factor 21TLR4 toll-like receptor 4NAD nicotinamide adenine dinucleotideACE angiotensin-I converting enzymeAT2R activity of angiotensin 2 receptorsCOVID-19 Coronavirus disease 2019Respiratory distressACE2 angiotensin converting enzyme 2MKP-1 mitogen-activated protein kinase phosphatase-1 ()PD protease domainSNP single nucleotide polymorphismEH essential hypertensionTNFR tumor necrosis factor receptorINR international normalized ratio of the prothrombin timePAI-1 plasminogen activator inhibitor-1Ang angiotensinLPS lipopolysaccharideMCP1 monocyte chemoattractant protein-1medicine.symptomaPTT partial thromboplastin timeBiotechnologyDUSP1 dual specificity phosphatase 1Coronavirus disease 2019 (COVID-19)PC prostate cancerRAS renin-angiotensin aldosterone systemCCR5Δ32 genetic variant of chemokine receptorCOVID-19 Researching genetic basis of resistance and potential pharmacological targets Italian nonagenarians/centenarians Longevity modelAsymptomaticSARS-1 severe acute respiratory syndrome virus 1SIRT-1 Sirtuin 1Th1 t-helper lymphocyte type 1Immune systemROS reactive oxygen speciesTGF-β transforming growth factor betaET-1 endothelin-1ComputingMethodologies_COMPUTERGRAPHICSADAM-17 metallopeptidase domain 17business.industrySARS-CoV-2SBP systolic blood pressureCOVID-19HDACs histone deacetylasesComorbidityImmune Systembusiness5-LO lipoxygenase 5Ageing Research Reviews
researchProduct

Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching

2017

Introduction Current treatment with vasodilators for pulmonary hypertension associated with respiratory diseases is limited by their inhibitory effect on hypoxic pulmonary vasoconstriction (HPV) and uncoupling effects on ventilation-perfusion (V'/Q'). Hypoxia is also a well-known modulator of the nitric oxide (NO) pathway, and may therefore differentially affect the responses to phosphodiesterase 5 (PDE5) inhibitors and soluble guanylyl cyclase (sGC) stimulators. So far, the effects of the sGC stimulator riociguat on HPV have been poorly characterized. Materials and methods Contraction was recorded in pulmonary arteries (PA) in a wire myograph. Anesthetized rats were catheterized to record …

MaleAnoxemiaPulmonologyPulmonary FibrosisVasodilator Agentslcsh:MedicineVasodilation030204 cardiovascular system & hematologyPharmacologyVascular Medicinechemistry.chemical_compound0302 clinical medicineSoluble Guanylyl CyclaseHypoxic pulmonary vasoconstrictionPulmonary fibrosisMedicine and Health SciencesPulmonary Arterieslcsh:ScienceHypoxiaMultidisciplinaryVasodilatorsDrugsRespiratory organs diseasesArteriesMiddle AgedChemistryPhysical Sciencescardiovascular systemFemalemedicine.symptomAnatomyMedicamentsmedicine.drugResearch ArticleChemical Elementsinorganic chemicalsSildenafilHypertension PulmonaryChronic Obstructive Pulmonary DiseaseEnzyme ActivatorsIn Vitro TechniquesPulmonary ArteryRiociguatSildenafil CitrateMalalties de l'aparell respiratori03 medical and health sciencesMedical HypoxiamedicineVentilation-Perfusion RatioAnimalsHumansRats WistarAgedPharmacologybusiness.industrylcsh:RAnoxèmiaBiology and Life SciencesHypoxia (medical)Phosphodiesterase 5 Inhibitorsmedicine.diseasePulmonary hypertensionFibrosisRatsOxygenDisease Models AnimalPyrimidines030228 respiratory systemchemistryVasoconstrictionCardiovascular AnatomyPyrazolesBlood Vesselslcsh:QSoluble guanylyl cyclasebusinessDevelopmental Biology
researchProduct

Recanalization Therapies in Acute Ischemic Stroke Patients Impact of Prior Treatment With Novel Oral Anticoagulants on Bleeding Complications and Out…

2015

Background— We explored the safety of intravenous thrombolysis (IVT) or intra-arterial treatment (IAT) in patients with ischemic stroke on non-vitamin K antagonist oral anticoagulants (NOACs, last intake <48 hours) in comparison with patients (1) taking vitamin K antagonists (VKAs) or (2) without previous anticoagulation (no-OAC). Methods and Results— This is a multicenter cohort pilot study. Primary outcome measures were (1) occurrence of intracranial hemorrhage (ICH) in 3 categories: any ICH (ICH any ), symptomatic ICH according to the criteria of the European Cooperative Acute Stroke Study II (ECASS-II) (sICH ECASS-II ) and the National Institute of Neurological Disorders and Stroke …

MaleBrain Ischemia/blood/drug therapyVitamin Kmedicine.medical_treatmentendovascular proceduresAnticoagulants/administration & dosage/adverse effects/classification/therapeutic useAdministration OralPilot ProjectsTissue plasminogen activatorBrain IschemiaCohort Studies2737 Physiology (medical)Atrial Fibrillation80 and overThrombolytic TherapyVitamin K/antagonists & inhibitorsStrokethrombolytic therapyAged 80 and overIncidenceAtrial fibrillationThrombolysisMiddle Aged3. Good healthvitamin K antagonistsTreatment OutcomeAdministrationAcute DiseaseCohortCerebral Hemorrhage/chemically induced/epidemiologyFemaleCardiology and Cardiovascular MedicineAtrial Fibrillation/complicationsmedicine.drugOralmedicine.medical_specialtyanticoagulantsnon-vitamin K antagonist oral anticoagulantsFactor Xa Inhibitors/administration & dosage/adverse effects/therapeutic useintracranial hemorrhagesintra-arterial treatment610 Medicine & healthAntithrombins2705 Cardiology and Cardiovascular MedicineDabigatranFibrinolytic AgentsPhysiology (medical)Internal medicinemedicineischemic strokeHumansAgedCerebral HemorrhageIntracerebral hemorrhageFibrinolytic Agents/therapeutic usebusiness.industryAntithrombins/administration & dosage/adverse effects/therapeutic usemedicine.diseaseddc:616.810040 Clinic for Neurologyanticoagulants; endovascular procedures; intra-arterial treatment; intracranial hemorrhages; ischemic stroke; non-vitamin K antagonist oral anticoagulants; thrombolytic therapy; vitamin K antagonistsPropensity score matchingbusinessFactor Xa InhibitorsCirculation
researchProduct

Amplification of ETS2 oncogene in acute nonlymphoblastic leukemia with t(6;21;18).

1992

Cytogenetic and molecular studies in a case of acute nonlymphoblastic leukemia (ANLL) are reported in this paper. Bone marrow blasts carried a hypodiploid karyotype with a complex t(6;18;21)(6qter----6p21::21q22----21qter;18qter ----18p11::6p22----6pter; 21pter----21q22::6p21----6p22::18p11----18pte r) and other numerical and structural changes. We studied the organization and the expression of the ETS2 gene which is located on chromosome 21 in order to investigate its possible involvement in the disease. DNA analysis showed a 20-fold amplification of ETS2 sequences; an increase of 3- to 4-fold in the mRNAs level compared to normal was shown by Northern hybridization.

MaleCancer ResearchChromosomes Human Pair 21Chromosomal translocationBiologyTranslocation GeneticProto-Oncogene Protein c-ets-2Proto-Oncogene ProteinsGene duplicationGeneticsmedicineHumansNorthern blotMolecular BiologySouthern blotAgedChromosome AberrationsOncogeneGene AmplificationKaryotypeProtein-Tyrosine KinasesBlotting NorthernMolecular biologyDNA-Binding ProteinsRepressor ProteinsBlotting SouthernLeukemia Myeloid Acutemedicine.anatomical_structureCancer researchTrans-ActivatorsChromosomes Human Pair 6Bone marrowChromosome 21Chromosomes Human Pair 18Transcription FactorsCancer genetics and cytogenetics
researchProduct

The genomic and clinical landscape of fetal akinesia

2020

International audience; Fetal akinesia has multiple clinical subtypes with over 160 gene associations, but the genetic etiology is not yet completely understood.Methods: In this study, 51 patients from 47 unrelated families were analyzed using next-generation sequencing (NGS) techniques aiming to decipher the genomic landscape of fetal akinesia (FA).Results: We have identified likely pathogenic gene variants in 37 cases and report 41 novel variants. Additionally, we report putative pathogenic variants in eight cases including nine novel variants. Our work identified 14 novel disease-gene associations for fetal akinesia: ADSSL1, ASAH1, ASPM, ATP2B3, EARS2, FBLN1, PRG4, PRICKLE1, ROR2, SETBP1…

MaleCandidate geneMyopathyVARIANTSFetal akinesiaMESH: Ryanodine Receptor Calcium Release Channel0302 clinical medicineMESH: ChildGuanine Nucleotide Exchange FactorsMESH: Guanine Nucleotide Exchange FactorsExomeCopy-number variationChildExomeMESH: High-Throughput Nucleotide SequencingGenetics (clinical)GeneticsArthrogryposisArthrogryposis0303 health sciencesMESH: Infant NewbornMESH: Genetic Predisposition to DiseaseHigh-Throughput Nucleotide SequencingRNA-Binding ProteinsMESH: Infant3. Good healthFetal DiseasesCopy-number variationMESH: Fetal DiseasesMESH: Young AdultChild PreschoolASAH1FemaleMESH: DNA Copy Number Variationsmedicine.symptomAdultGENETICSAdolescentDNA Copy Number VariationsMESH: Trans-ActivatorsMESH: ArthrogryposisBiologyASPMYoung Adult03 medical and health sciencesMuscular DiseasesmedicineHumansGenetic Predisposition to DiseaseGene030304 developmental biologyMESH: Adolescent[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/PediatricsMESH: HumansMUTATIONSMESH: Child PreschoolInfant NewbornMESH: Muscular DiseasesInfantNEMALINE MYOPATHYRyanodine Receptor Calcium Release ChannelMESH: Adultmedicine.diseaseCongenital myopathyMESH: MaleMESH: RNA-Binding Proteins[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsDISTAL ARTHROGRYPOSISTrans-ActivatorsMESH: Female030217 neurology & neurosurgery
researchProduct